HomeCompareAMPE vs PLD

AMPE vs PLD: Dividend Comparison 2026

AMPE yields 1311.05% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMPE wins by $207537748.94M in total portfolio value
10 years
AMPE
AMPE
● Live price
1311.05%
Share price
$0.15
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$207537754.85M
Annual income
$180,460,634,612,456.80
Full AMPE calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — AMPE vs PLD

📍 AMPE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMPEPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMPE + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMPE pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMPE
Annual income on $10K today (after 15% tax)
$111,438.87/yr
After 10yr DRIP, annual income (after tax)
$153,391,539,420,588.28/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, AMPE beats the other by $153,391,535,382,471.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMPE + PLD for your $10,000?

AMPE: 50%PLD: 50%
100% PLD50/50100% AMPE
Portfolio after 10yr
$103768880.38M
Annual income
$90,230,319,681,591.00/yr
Blended yield
86.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

AMPE
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-63.7
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMPE buys
0
PLD buys
0
No recent congressional trades found for AMPE or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMPEPLD
Forward yield1311.05%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$207537754.85M$5.91M
Annual income after 10y$180,460,634,612,456.80$4,750,725.19
Total dividends collected$205538221.53M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: AMPE vs PLD ($10,000, DRIP)

YearAMPE PortfolioAMPE Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$141,805$131,104.56$11,241$540.96+$130.6KAMPE
2$1,889,228$1,737,497.51$13,019$991.13+$1.88MAMPE
3$23,655,368$21,633,893.61$15,801$1,870.97+$23.64MAMPE
4$278,471,869$253,160,624.79$20,609$3,701.21+$278.45MAMPE
5$3,083,213,738$2,785,248,838.88$29,919$7,867.97+$3083.18MAMPE
6$32,119,606,169$28,820,567,469.38$50,631$18,617.74+$32119.56MAMPE
7$314,966,468,315$280,598,489,713.88$105,528$51,352.20+$314966.36MAMPE
8$2,908,568,193,145$2,571,554,072,047.85$287,364$174,449.42+$2908567.91MAMPE
9$25,305,719,846,817$22,193,551,880,152.03$1,081,760$774,280.77+$25305718.77MAMPE
10$207,537,754,848,551$180,460,634,612,456.80$5,908,209$4,750,725.19+$207537748.94MAMPE

AMPE vs PLD: Complete Analysis 2026

AMPEStock

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

Full AMPE Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this AMPE vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMPE vs SCHDAMPE vs JEPIAMPE vs OAMPE vs KOAMPE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.